Delving into the Latest Updates on COVID-19(Auransa) with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

COVID-19

Inactive Indication-

Originator Organization

Auransa, Inc.

Active Organization

Auransa, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Despite the greater risk of adverse COVID-19 outcomes, antibody and cell-mediated immune responses to COVID-19 vaccines vary amongst immunocompromised (IC) people and are poorly defined. IC hosts were largely excluded from the COVID-19 vaccine registration trials, though many countries recommend additional and booster doses of vaccination in this group.
BOOST-IC is an adaptive randomised clinical trial (RCT) to assess the immunogenicity and safety of additional COVID-19 vaccine doses in immunocompromised (IC) people, including people with HIV, solid organ transplants (SOT) recipients or those with haematological malignancies. Briefly, the study aims to generate high-quality evidence on the immunogenicity and safety of alternative COVID-19 booster strategies against SARS-CoV-2 for IC people in Australia.

Start Date01 Dec 2022

Sponsor / Collaborator

Great Lakes Bay Health Centers

[+1]

NCT04853108

/ TerminatedNot ApplicableIIT

Using Telemedicine, Remote Physiologic Monitoring, and Mobile Self-reported Symptom Surveys to Improve Care for COVID-19 Patients

This study seeks to evaluate how secondary data retrieved from remote physiological monitoring performed during routine outpatient/at-home care periods can allow for the discovery of novel physiomarkers that predict acute deterioration or hospitalization among people testing positive for Coronavirus Disease 2019 (COVID-19).

Start Date25 Jun 2021

Sponsor / Collaborator

Emory University

[+1]

100 Clinical Results associated with COVID-19(Auransa)

Login to view more data

100 Translational Medicine associated with COVID-19(Auransa)

Login to view more data

100 Patents (Medical) associated with COVID-19(Auransa)

Login to view more data

7

Literatures (Medical) associated with COVID-19(Auransa)

01 Dec 2022·American Journal of Hematology

Increased CD8 T‐cell immunity after COVID‐19 vaccination in lymphoid malignancy patients lacking adequate humoral response: An immune compensation mechanism?

Letter

Author: Van Elssen, Catharina H. M. J. ; van Gorkom, Gwendolyn N. Y. ; van Loo, Inge H. M. ; Heemskerk, Mirjam H. M. ; Dijkland, Romy C. ; Pothast, Cilia R. ; Boerenkamp, Lara S. ; Wieten, Lotte ; van Dijk, Kayleigh ; Halkes, Constantijn J. M.

In this article studies about an immune compensation mechanism of increased CD8 T-cell immunity after COVID -19 vaccination in lymphoid malignancy patients lacking adequate humoral response.In conclusion, this study demonstrates that the majority of patients lacking adequate seroconversion following SARS-CoV-2 mRNA vaccination were able to generate a cellular immune response.Moreover, a hampered humoral response is compensated by a stronger cellular response, which indicates that vaccination is of significance also in patients lacking seroconversion.

01 Aug 2022·British Journal of Dermatology

Evaluating risk of bullous pemphigoid after mRNA COVID ‐19 vaccination

Letter

Author: Karris, Maile Y. ; Kaelber, David C. ; Paravar, Taraneh ; Birabaharan, Morgan ; Orme, Charisse M.

This study is on the evaluating risk of bullous pemphigoid after mRNA COVID -19 vaccination.We performed a retrospective cohort study using the Tri-NetX analytics network (trinetx.com; Cambridge, MA, USA), a federated health research network that aggregates health records from 63 healthcare organizations, compromising 70 million patients.Our results suggest mRNA COVID-19 vaccination is not associated with increased risk of new-onset bullous pemphigoid.Other limitations to consider include the use of population data, which have inherent misclassification bias from the use of ICD codes.Lastly, participants may have developed bullous pemphigoid without seeking care.

01 Apr 2022·The Journal of the Association of Physicians of India

Breakthrough covid 19 infections after 2 doses of covid 19 vaccination and comparing severity between hospitalized and non hospitalized in tertiary care hospital.

Article

Author: S, Mohith ; Hr, Chandrashekhar

The COVID 19 infection is highly transmissible and spreading globally, including in populations with high vaccination rates. COVID-19 vaccination in India, was started in month of January 2021 with healthcare workers (HCWs) becoming the first to get vaccinated. However, there has been lot debate on the efficacy of the vaccine. This study highlights breakthrough COVID-19 infections among vaccinated HCWs comparing clinical and lab parameter among hospitalized and non hospitalized.MATERIALThis was a retrospective study conducted using questionnaire assessing COVID-19 like symptoms and confirmed COVID 19 infections among fully vaccinated HCWs (all faculty including nurses, wardboys, professors, post graduate students and interns) of the institute from a period of 4 months from March 2021 to June 2021. The number of infections was also matched with hospital records.OBSERVATIONOut of 36 HCWs, all had received both doses of covishield vaccine. Males were 18 and females were 18, mean age was found to ne 32.17. People with co-morbidities were 13.9% including diabetes and hypertension. Out 36 HCWs, 4 people required hospitalization ie 11%, all other cases had mild symptoms and none required oxygen support. There was no significant difference between hospitalized and non-hospitalized with regard to routine lab parameters, but there significant elevation of inflammatory marker -CRP being positive in 2 hospitalized cases, with p value being significant (p<0.001).CONCLUSIONThis study identifies that breakthrough infections among vaccinated HCWs(health care workers) were common. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur. The findings suggested that COVID-19 were more severe in hospitalized patients compared to non-hospitalized and even though infections did occur none resulted in any severe form or mortality, it also indicates that vaccination prevents from severe form of the disease. But, preventive measures should be continued even among vaccinated individuals.

100 Deals associated with COVID-19(Auransa)

Login to view more data